Endocrine-Related Cancer

Article	Citations
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms	73
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms	55
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	49
Therapy considerations in neuroendocrine prostate cancer: what next?	44
The role of vitamin D in breast cancer risk and progression	42
The tumor microenvironment and immune responses in prostate cancer patients	42
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?	35
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns	34
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy	34
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas	34
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	33
Thyroid cancer in the age of COVID-19	32
Redifferentiation-facilitated radioiodine therapy in thyroid cancer	31
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)	28
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues	27
Molecular alterations in Hürthle cell nodules and preoperative cancer risk	27
New therapeutic opportunities for women with low-grade serous ovarian cancer	26
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches	25
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?	24
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	24
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment	24
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	23
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas	23
Androgen receptor mutations for precision medicine in prostate cancer	22
Novel insights in cell cycle dysregulation during prostate cancer progression	22

Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison	21
Genomic classification of benign adrenocortical lesions	21
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	21
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway	20
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes	20
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers	20
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer	20
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives	18
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	18
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer	18
Genome-wide crosstalk between steroid receptors in breast and prostate cancers	18
Tailoring the approach to radioactive iodine treatment in thyroid cancer	18
Risk factors for intraoperative complications in pheochromocytomas	18
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs	17
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	17
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro	17
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism	17
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC	17
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians	17
Translating the immune microenvironment of thyroid cancer into clinical practice	16
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors	16
The role of membrane mucin MUC4 in breast cancer metastasis	16
Metastatic medullary thyroid carcinoma: a new way forward	16
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures	16
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs	15
Targeted genomic analysis of 364 adrenocortical carcinomas	15
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment	15
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism	15
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging	14
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	14
Molecular connections between circadian rhythm and genome maintenance pathways	14
Critical appraisal of MGMT in digestive NET treated with alkylating agents	14
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview	14
Adiponectin receptor activation inhibits prostate cancer xenograft growth	14
Changing biological behaviour of NETs during the evolution of the disease: progress on progression	13
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	13
Gene expression profile in metastatic and non-metastatic parathyroid carcinoma	13
Serine synthesis influences tamoxifen response in ER+ human breast carcinoma	13
The thyroid risk score (TRS) for nodules with indeterminate cytology	13
100 years of the Warburg effect: a historical perspective	12
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers	12
Percutaneous ablation of low-risk papillary thyroid cancer	12
Update on the genetics of paragangliomas	12
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	12
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy	11
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	11
BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation	11
Leptin-elicited PBX3 confers letrozole resistance in breast cancer	11
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings	11
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis	11

Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics	11
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	11
Advances in paraganglioma–pheochromocytoma cell lines and xenografts	11
Stress hormone norepinephrine incites resistance of oral cancer cells to chemotherapy	11
Remodelling of colorectal cancer cell signaling by microbiota and immunity in diabetes	10
Exploring stem cell biology in pituitary tumors and derived organoids	10
Dysregulation of splicing variants and spliceosome components in breast cancer	10
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	10
Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion	10
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	10
Leptin antagonism inhibits prostate cancer xenograft growth and progression	10
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	10
Aggressive versus indolent insulinomas: new clinicopathological insights	10
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	10
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)	10
Adrenal tumors provide insight into the role of cortisol in NK cell activity	10
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	10
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma	10
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	9
Metabolomics in paraganglioma: applications and perspectives from genetics to therapy	9
Effect of TSH levels during active surveillance of PTMC according to age	9
Targeting androgen receptor signaling: a historical perspective	9
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	9
Immunotherapy-induced isolated ACTH deficiency in cancer therapy	9
Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development	9
Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation	9
PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A	9
Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?	8
GH and IGF1 in cancer therapy resistance	8
Somatostatin receptor radionuclide therapy in neuroendocrine tumors	8
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality	8
Congenital hypothyroidism and thyroid cancer	8
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	8
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma	8
Alert to US physicians: DHEA, widely used as an OTC androgen supplement, may exacerbate COVID-19	8
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	8
Cancer-associated adipocytes release FUCA2 to promote aggressiveness in TNBC	8
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	8
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	8
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	8
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	7
Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis	7
Hypothyroidism induces oxidative stress and DNA damage in breast	7
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis	7
FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC	7
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	7
Functional significance of germline EPAS1 variants	7
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites	7
Cancer clocks in tumourigenesis: the p53 pathway and beyond	7
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors	7
Diagnostic and management strategies for pNETs in Von Hippel–Lindau: a systematic review	7
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	7
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	7
Global longitudinal strain as a marker for systolic function in patients with pheochromocytomas	7
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	7
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	6
Cell diversity and immune infiltration in the parathyroid tumour microenvironment	6
Cancer in growth hormone excess and growth hormone deficit	6
Urinary androgens excretion patterns and prostate cancer in Mexican men	6
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	6
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	6
Radioiodine treatment: an historical and future perspective	6
ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways	6
The association between serum concentration of thyroid hormones and thyroid cancer: a cohort study	6
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	6
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	6
Non-pituitary GH regulation of the tissue microenvironment	6
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	6
Single nucleotide polymorphisms in matrix metalloproteinase 2 (MMP2) enhance BRAFV600E mutation-mediated oncogenicity and invasiveness of papillary thyroid cancer cells	6
Evaluation of modifiable factors and polygenic risk score in thyroid cancer	6
Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours	6
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	5
A pilot study of everolimus and radiation for neuroendocrine liver metastases	5
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	5
Insulinomatosis: new aspects	5
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors	5
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	5

Serum TSH is not a risk factor for malignancy of pediatric thyroid nodules	5
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	5
Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells	5
Germline CDKN1B variant type and site are associated with phenotype in MEN4	5
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	5
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	5
Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics	5
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	5
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	5
Real-time, high-resolution imaging of tumor cells in genetically engineered and orthotopic models of thyroid cancer	5
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition	5
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	5
CGM for insulinoma screening: a prospective and observational case-control study	5
Emerging therapies for advanced insulinomas and glucagonomas	4
Efficacy of adavosertib therapy against anaplastic thyroid cancer	4
The effect of thyroid dysfunction on breast cancer risk: an updated meta-analysis	4
Pregnancy-associated breast cancer: the influence of gestational age	4
Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?	4
Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region	4
Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview	4
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	4
Celebrating the 80th anniversary of hormone ablation for prostate cancer	4
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	4
Malignant thyroid teratoma: an integrated analysis of case series/case reports	4
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors	4
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	4
A study of acromegaly-associated headache with somatostatin analgesia	4
Mendelian randomization supports a causative effect of TSH on thyroid carcinoma	4
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	4
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma	4
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy	4
Role of PDK4 in insulin signaling pathway in periadrenal adipose tissue of pheochromocytoma patients	4
TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT axis	4
The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study	4
Target therapies plus somatostatin analogs in NETs: a network meta-analysis	4
Genetic biomarkers of life-threatening pheochromocytoma-induced cardiomyopathy	4
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	4
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	4
miR-126-3p contributes to parathyroid tumor angiogenesis	4
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	4